The physiological consequence so far is unknown; however, our study suggests that Trx1 can be regarded as a potential marker for autoimmune bullous skin diseases, while systemic loss of Prx4 and Grx2 indicates a beneficial therapeutic impact by external CAP application, resulting in a reactivation of oxidative eustress in pemphigus. This evidence concerns the gene PRDX4 and autoimmune bullous skin disease.